Clinical_Pharmacology_Fact_Sheet

C L I N I C A L P H A R M A C O L O G Y

G L O B A L P R E S E N C E

CLINICALPHARMACOLOGY

With 30+ years of experience delivering clinical and bioanalytical laboratory services, PRA Health Sciences understands how to help clients achieve challenging early phase development goals. PRA’s group conducts complex early clinical trials in healthy volunteers and patients through state-of-the-art facilities and innovative patient networks in the US and Europe. Our GLP-compliant bioanalytical laboratories are located close to the clinical units, enabling us to quickly analyze time-critical samples.

I N N O VAT I O N

Committed to the highest standards of clinical excellence and scientific expertise, PRA excels at research and development through proactive, forward-thinking strategies. We consistently deliver innovative solutions to our clients through our investment in best-in-class technology and commitment to continuous improvement.

Our Patient Pharmacology Services group features a unique scientific, medical, and operational framework that enables us to conduct early phase patient studies within the same standards as any other Phase I or Phase IIa trial, but at locations where the patients can be recruited and monitored for the entire study.

Our innovative and very flexible designs allow us to define the appro-priate operational strategy according to project-specific requirements. We tailor each client's solutions based upon 3 core elements:

• PRA Phase I Patient Centers: Study performance in one of our own Phase I centers in Prague, Budapest, or Bratislava.

• PRA Operated Sites: PRA medical and clinical operational staff support study conduct at external hospitals, thereby enabling a Phase I setting at sites with direct access to patient populations.

• PRA Managed Sites: Management of independent specialized investigational sites in the Central and Eastern Europe area or abroad.

E X P E R T I S E

Phase I/IIa Phase II/III Phase IV

PRA Managed Sites

PRA Operated Sites

PRA PatientPhase I Units

No. OF CLINICAL RESEARCH UNITS

88No. OF PATIENT BEDS

450450450450“The most comprehensive, high-end, Phase I CRO in the world”WILLEM JAN DRIJFHOUT, Executive Vice President, Early Development Services

Salt Lake City, UT, USALenexa, KS, USAMarlton, NJ, USAZuidlaren/Groningen, NLBerlin, GermanyPrague, Czech RepublicBratislava, Slovak RepublicWarsaw, PolandBudapest, HungaryMoscow, Russia

Single Ascending DoseMultiple Ascending DoseEfficacy in PatientsFood, Age, Gender EffectBiosimilars

ADMEBioequivalenceDrug/drug InteractionRenal/hepatic ImpairedHuman Abuse LiabilityThorough QTc

Special Formulations

PRA Health Sciences conducts comprehensive phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at [email protected] Health Sciences conducts comprehensive Phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at [email protected].

When it comes to clinical pharmacology, our 1,000+ early phase scientists and operational professionals are driven. Our people are driven by an unwavering commitment to client service and compassion for patients who urgently need safe, e�ective drug treatments. By an empowered environment that promotes innovative, creative solutions that change the way we think about clinical development. And by our passion for redefining what it means to excel at clinical research and truly deliver quality results for clients and patients.

For those reasons and many more, our commitment to you has never been stronger than it is today.